Fredun Pharmaceuticals Ltd
Incorporated in 1987, Fredun Pharmaceuticals
Ltd manufactures & exports healthcare and pharmaceuticals products[1]
- Market Cap ₹ 381 Cr.
- Current Price ₹ 807
- High / Low ₹ 904 / 635
- Stock P/E 19.3
- Book Value ₹ 299
- Dividend Yield 0.09 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 2.70 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2025 | |
---|---|
456 | |
401 | |
Operating Profit | 55 |
OPM % | 12% |
0 | |
Interest | 22 |
Depreciation | 5 |
Profit before tax | 27 |
Tax % | 28% |
20 | |
EPS in Rs | 41.81 |
Dividend Payout % | 2% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | % |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | % |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 34% |
3 Years: | 0% |
1 Year: | -5% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2025 | |
---|---|
Equity Capital | 5 |
Reserves | 137 |
167 | |
179 | |
Total Liabilities | 487 |
53 | |
CWIP | 0 |
Investments | 2 |
433 | |
Total Assets | 487 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2025 | |
---|---|
-29 | |
-6 | |
39 | |
Net Cash Flow | 4 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2025 | |
---|---|
Debtor Days | 142 |
Inventory Days | 265 |
Days Payable | 160 |
Cash Conversion Cycle | 247 |
Working Capital Days | 202 |
ROCE % |
Documents
Announcements
-
Voluntary Disclosure - SEBI Adjudication Order Dated June 30, 2025 (No Penalty Imposed)
23h - SEBI adjudication order on LODR violations; no penalty imposed on Fredun Pharmaceuticals.
-
Closure of Trading Window
30 Jun - Trading window closed from July 1, 2025, till 48 hours post Q1 financial results approval.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
30 Jun - Fredun acquires One Pet Stop, entering pet care market with 4,000+ customers and tech-enabled grooming services.
-
Announcement under Regulation 30 (LODR)-Demise
20 Jun - Death of promoter director Nariman Medhora holding 15.24% shares on 20 June 2025.
-
Investors Presentation Issued By Fredun Pharmaceuticals Limited Stating Annual Review & Strategic Outlook For Growth In The Pharma Industry
10 Jun - Fredun Pharmaceuticals' June 2025 investor presentation on annual review, growth strategy, and product expansions.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Business Overview:[1]
The company, a subsidiary of the Fredun Group, manufactures pharmaceutical and allopathic formulations including tablets, syrups, capsules, and ointments across therapeutic areas like anti-diabetics, anti-retrovirals, and anti-hypertensives. It has also expanded into dietary and herbal supplements, nutraceuticals, diagnostic kits, and animal healthcare products through group entities Fredun Healthcare Pvt. Ltd. and Fredna Enterprises.